key: cord-0727751-j0phmf61 authors: Weiss, Peter title: Pandemic Woes: Antigen Tests to the Rescue? date: 2020-12-10 journal: Engineering (Beijing) DOI: 10.1016/j.eng.2020.12.002 sha: 63b74e8b8e89ff05c069b775680e29d05703f27e doc_id: 727751 cord_uid: j0phmf61 nan USA, the number of tests needed to screen the general population in the United States may be more than double that needed just for schools. ''Now is the time," Aspinall said, ''We have the protocols. We have the tests. I hope we have the community will to reduce transmission and take back control." Tests using the reverse transcription-polymerase chain reaction (RT-PCR) currently serve as the gold standard for making COVID-19 diagnoses [8] . However, such conventional testing is complicated, costly, and slow, taking hours to run a sample through multiple, temperature-controlled steps. It also relies on skilled technicians, expensive reagents, and specialized processing laboratories to which samples often must be shipped, further delaying results. When COVID-19 infection rates are low and nations have been able to avoid surges of cases, RT-PCR testing appears to work well. But when caseloads climb steeply, as they have continued to do in many countries, RT-PCR laboratories cannot keep up with demand. Under such conditions, delays of days and sometimes a week or more in reporting results greatly reduces the value of the tests for guiding public health efforts to prevent further disease spread. Their expense also makes them ill-suited for the rapid and frequent testing critically needed to identify asymptomatic and presymptomatic carriers of the virus who could unknowingly spread the disease to others [9] . RT-PCR detects viruses with extraordinary accuracy by seeking out and replicating strands of their genetic material by the billions. In contrast, ''lateral-flow antigen assays," like the 150 million Abbott ''BinaxNOW" COVID-19 tests purchased by the US government, detect the virus-generally with less fidelity than RT-PCRby capturing proteins, or ''antigens," unique to the virus with custom-designed antibodies, a process that importantly enables ''while-you-wait" results. Manufacturers have reported official sensitivities and specificities for many antigen tests that rival those of RT-PCR, but this accuracy generally only applies during a brief window of high viral load during the first five days after the onset of symptoms and not to asymptomatic and presymptomatic carriers, in whom the accuracy of many antigen tests has yet to be determined. With the Abbott BinaxNOW test (Fig. 1) , which is not approved for self-administration, a healthcare professional inserts a test swab from a patient into a tiny well of reagent in the test card to produce a sample solution that migrates by capillary motion along a fibrous strip through a patch of loosely deposited antibodies tagged with colloidal gold. If target proteins are in the sample, the antibodies capture those molecules to form antigen-antibodytag complexes that continue to flow. Awaiting that flow downstream, a fixed, ''test" line of a different kind of antibodies capture the complexes themselves. The trapped gold tags make the line become visible to the naked eye, indicating a positive result. Taking place entirely at room temperature, the 15 min test requires no readout device or other instruments. Long used to quickly diagnose illnesses such as influenza, legionella, strep throat, and acquired immune deficiency syndrome (AIDS), among others, antigen assays are not new. But the urgency of the COVID-19 pandemic has spurred the unprecedentedly quick development of new antigen-based and other rapid tests. When the COVID-19 pandemic began, manufacturers foresaw a potentially tremendous demand for antigen tests. Their first steps included investigating which proteins might serve best as markers of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Complementary molecules-primarily antibodies-able to recognize and bind those markers also had to be designed and created. Developing just the nine antigen-based assays approved so far by regulators for emergency use has involved combining advanced technologies including microfluidics [10] ; nanomaterials (which can influence test sensitivity and speed, readout type, and whether a separate analytical instrument is required); various methods for signaling the presence of the virus such as chromatography [11] , fluorescence [12] , and electrochemical sensing [13] ; and manufacturing integration to produce tests that simultaneously assay for multiple, distinct pathogens-like COVID-19, influenza, and respiratory syncytial virus-in a single instrument [14] . As of early November 2020, the COVID-19 Testing Commons, a public database maintained at ASU by Aspinall and others [4], listed about 1000 tests available or in development worldwide for detecting active SARS-CoV-2 infections, plus another 1000 antibody tests, used to identify individuals who have had COVID-19 but not those with active infections. The bulk of the database entries for active infection tests, about 75%, fall into the RT-PCR category, mostly variations on that laboratory standard that speed up, simplify, or lessen the cost of its complex process. While 10%plus are lateral-flow antigen assays, with more than 100 such tests listed as in development, another nearly 150 listings represent cutting-edge prototypes and concepts based on a broad range of novel technologies. Nine of these, including two granted US FDA EUAs [15, 16] , make use of clustered regularly interspaced short palindromic repeats (CRISPR) [17] , the acclaimed gene-editing technology recognized this year with the Nobel Prize in Chemistry [18] . Several others harness artificial intelligence, such as a test in development at Oxford University in the United Kingdom that combines microscopic imaging, fast fluorescent labeling, and neural-network analysis to ascertain presence of the virus within 5 min [19] . Multiple companies, including collaborators Gauss (Menlo Park, CA, USA) and Cellex (Research Triangle Park, NC, USA), are incorporating another enhancement that addresses concerns about result verification and reporting, devising tests with results readable only by means of smartphone apps that also securely communicate test results to public health or other authorities [20] . But even the RT-PCR category includes much innovation. The ''CovidNudge," for example, a highly miniaturized RT-PCR test, takes just 90 min to run a full RT-PCR cycle in a portable, wall-powered, automated lab-in-a-box about the size of a toaster (Fig. 2 ) [21] . In trials conducted in three UK hospitals from April to May 2020, the overall accuracy of this point-of-care test, performed without laboratory handling or sample pre-processing, was shown to be comparable to standard RT-PCR laboratory testing [21] , prompting the UK government to place a 212 million USD order for 5.8 million test kits for use in National Health Service hospitals beginning in September 2020 [22] . How all these new tests will impact the pandemic-and how they will complement the expected vaccines to come-remains to be determined. But while the experts continue to scrutinize and debate their potential utility, especially for identifying asymptomatic and presymptomatic carriers who may be infectious [23] [24] [25] , governments, philanthropies, and the global healthcare community are nonetheless rushing to acquire and deploy them by the millions [2, 22, [26] [27] [28] . The increasing availability of rapid testing options is ''a very positive advancement," but still ''a work in progress," said infectious disease epidemiologist Maria van Kerkhove, the World Health Organization's technical lead for COVID-19 and an honorary lecturer at the Imperial College of London School of Public Health. ''Countries are using them, so we are trying to provide guidance on where they perform better, to alleviate some of the pressure on PCR." 2 . The CovidNudge test showcases recent innovation in RT-PCR, the healthcare industry gold standard for detecting viral infections. When the top of the toastersize ''DnaNudge" testing instrument is slid into operating position over its bottom, the automated device conducts the complex genetics-based RT-PCR process on patient samples in the removable blue cartridge. Prior to the pandemic, DnaNudge's engineer-inventors at the Imperial College of London were already miniaturizing such clinical-laboratory-type equipment to speed up and make portable genetic analyses for a consumer-nutrition startup company. Repurposed to diagnose COVID-19 in healthcare settings and non-laboratory sites such as airports, schools, and large workplaces, the device carries out full RT-PCR for SARS-CoV-2 in less than 90 min, roughly a quarter of the time typically required by standard centralized laboratories and without the delays associated with sample transport. Credit: DnaNudge (public domain). Engineering xxx (xxxx) xxx Abbott's fast, $5, 15-minute, easy-to-use COVID-19 antigen test receives FDA emergency use authorization Abbotts-Fast-5-15-Minute-Easy-to-Use-COVID-19-Antigen-Test-Receives-FDA-Emergency-Use-Authorization-Mobile-App-Displays-Test-Results-to-Help-Our-Return-to-Daily-Life-Ramping-Production-to-50-Million-Tests-a-Month Trump administration will deploy 150 million rapid tests in 2020 US Department of Health and Human Services Individual EUAs for antigen diagnostic tests for SARS-CoV-2 US Food and Drug Administration WHO emergency use listing for in vitro diagnostics (IVDs) detecting SARS-CoV-2 [Internet]. Geneva: World Health Organization America needs to radically rethink our COVID-19 testing approach New York: The Rockefeller Foundation and Duke-Margolis Center for Health Policy What tests could potentially be used for the screening, diagnosis, and monitoring of COVID-19 and what are their advantages and disadvantages? Controlling the COVID-19 pandemic blindly: silent spread in absence of rapid viral screening Geffen: Avant Medical; c2020 Chromatographic immunoassays: strategies and recent developments in the analysis of drugs and biological agents Fluorescent immunoassays (FIA) Quidel Corporation Jersey City: Celltrion USA Sofia2 flu + SARS antigen FIA Quidel Corporation Sherlock Biosciences receives FDA emergency use authorization for CRISPR SARS-CoV-2 rapid diagnostic BioSewoom coronavirus tests CRISPR use in humans shows promise while experts weigh ethical concerns CRISPR genome editing gets 2020 Nobel Prize in Chemistry Chemical & Engineering News Oxford scientists develop extremely rapid diagnostic test for COVID-19 Tech startups developing rapid COVID-19 tests to be taken completely at home [Internet]. Framingham: FierceHealthcare Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study London: DnaNudge Rapid covid tests can work-if you avoid making the White House's mistakes A Rapid virus test falters in people without symptoms, study finds Rapid testing is less accurate than the government wants to admit Governor Hogan announces purchase of 250,000 rapid antigen tests through The Rockefeller Foundation's bipartisan interstate compact Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low-and middle-income countries BD receives order from Dutch Ministry of Health for more than nine million 15-minute COVID-19 antigen tests